|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
8/30/2012 7:27:41 AM
Genmab A/S (GEN), a Danish biotechnology company, rose the most in more than a year after it said Johnson & Johnson (JNJ) licensed its experimental treatment for multiple myeloma. Genmab shares rose as much as 25 percent, the biggest intraday gain since Aug. 9, 2011, and were up 20 percent to 81 kroner as of 10:25 a.m. in Copenhagen. The agreement with J&J’s Janssen unit for daratumumab may be worth at least $1.1 billion, including an upfront payment of $55 million, milestone payments, and an $80 million equity investment, Genmab said in a statement today. Daratumumab is a monoclonal antibody that may have potential in treating other types of cancers such as acute myeloid leukemia, Genmab said.
|
|
|
|
|
|
|
|
|
|
|